Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hmmmm, last I looked RGBP was between 20 cents and 30 cents. Never been below a penny, so the subpenny extract doesn't seem to apply here. But you might try the BMSN board for followers.
Never said it. On the other hand, to mock and make fun of the fact that having abstracts upgraded to oral presentations as insignificant, or meaningless or of the "scam" is total ignorance of reality and fact.
Such international conferences are sure to help create interest, exposure and possible co-development for the company. I, in fact, said not to expect C. Ichim to walk out with a contract in hand. But saying those presentations are nothing, as if a fifth grader or anyone could do it would mean you have no interest in the truth of the matter either.
So your criticisms and the way you state them, is as much a discredit as those who state them.
I think the days of needing a weekly PR update are past. There has been a lot of activity within the company this year, but I don't expect they'll have significant events each week for a PR.
My guesstimate for future PRs:
- early June for CRL safety test results update (not end of testing, but maybe a positive PR on initial test data progress)
- 2nd week August 10Q
- Sep announcement of filing test data with FDA
In between, there is no way to anticipate when news of significance might come on NR2F6 or NR2F2 compound hit for cancer stem cell differentiation or something else.
Personally, I have the feeling that dCellVax is still a work in progress and that with other NR2F6 developments, they might be fine tuning the dCellVax IND and waiting for CRL progress on HemaX before possibly having CRL do GLP studies for dCellVax IND.
I actually think it's a healthy thing that neither posters that only criticize and posters that say we are going to be millionaires next week because the process will be miraculously quick for RGBP's approvals are no longer having much sway on the PPS.
It may be frustrating to flippers and those who easily manipulated others on board to get overly excited or to panic unnecessarily. As each day passes, we come a day closer to knowing what the results of the CRL safety tests will be and one more day for the research on new possible INDs are occuring. The volatility of DT has passed as many DT have probably moved on.
There will be plenty of DT activity once CRL or FDA news comes out, but for now we are "holding" and waiting and getting closer.
So, in your opinion, if it falls below .20 at any point during the course of this year, your words ring true, but if someone else claims this will go above 1.00 or more, they are full of it, because a day or a week has gone by and we are still at .20-.30. Hmmm. Doesn't seem a fair standard.
We can all agree that unless and until FDA gives approval to something, RGBP will never have the legs to stand on to project this over a dollar or 5 dollars or what have you. We should all see that and be able to agree on that.
Let's talk about the new timeframe you give for the price to drop below .20 - "sometime during the course of this year". I think it is fair to say that others predictions of a "strong leg up", "skyrocket" and such will also occur sometime during the course of this year if FDA approves HemaX for human clinical trials and almost a guarantee to be over $1.00 if there is more than one FDA approval, i.e. HemaX and dCellVax (or other).
We are not there yet, but it's either going up or below .20 when news (good or bad) comes out from the FDA after the CRL safety tests. So let's keep the harsh back and forth to a minimum until then.
I fully agree, if CRL safety tests for HemaX are not accepted by FDA and no other RGBP IND has approval, then we go far below .20. But if FDA accepts and we go to human trials, say goodbye to .30/.40/.50 and who knows how high in my opinion, not forseeing some calamity.
Haha. Pinch, your prediction, repeated multiple times was for RGBP to fall below .20. Now, you've said it over and over and criticized others who say this is going to move quickly up. You call them false because RGBP is still between .20 and .30.
But what is your opinion of your own prediction? How many days until your prediction rings untrue?
I would agreed that RGBP is holding well because the selling volume is non existent. It's not going up, so I think the word holding is very appropriate here, wouldn't you agree? Holding, i.e. between the .20 and .30 range, especially since the sell volume that dipped it down to .23 was quickly reversed.
Curious. So it would make sense to you for RGBP to raise hundreds of thousands of dollars to hire employees and then contract with CRL to repeat the safety tests (that are the only non approved part of IND) "knowing" that there is no hope for approval?
Can you expand on that for us?
Ok. I stand corrected on the filing. You are aware that "aplastic anemia" has already been granted Orphan Status by the FDA, right? And BMSN has mentioned acquiring Orphan Drug status for HemaX, right? And the various benefits of Orphan Drug status occur upon approval of the treatment.
And, as the article you linked to states, companies will use filing and receiving Orphan Drug status for different reasons as to the timing. And there is no cost to file. So, the fact that BMSN/RGBP is waiting to file and receive this status (which aplastic anemia has already been designated as an Orphan Drug condition) is due to the timing/publicity effect of when they want to receive it. It's not a matter of incompetence, it's a matter of timing. Being able to issue a PR on HemaX human trial approval and then another PR shortly thereafter that they have received orphan drug status for HemaX in their minds probably carries more weight.
There is also the fact the Orphan Drug approvals are posted on FDA site for all competitors to see. They might want to be further along in the process before being listed, I couldn't say.
But the fact remains, Orphan Drug status will be a given whenever they want to apply because the FDA has already established aplastic anemia treatments as such.
You need to read more and do DD.
First - Orphan Status is not given without IND approval, but follows IND approval, so your comments there are unfactual.
Second - The fact we don't have dCellVax approval update should be clear from the science and past PRs. dCellVax has to meet the same clinical trials criteria of GLP that HemaXellerate would need to meet. The fact the HemaX tests did not meet the FDA criteria should clearly indicate that it will need retesting to establish results as does HemaX. And RGBP before Feb 2015 did not have the money to contract that out. Furthermore, the new IP being developed by Ichims has been stated in PRs to be in parallel to advancing dCellVax and they are looking into the best combo or effectiveness in studies. I would imagine that having chosen CRL to do the HemaX FDA studies, if successful, they will follow up and have CRL do the necessary studies for dCellVax. In fact, I would not be surprised if they are discussing dCellVax with CRL as to best plan to move forward. Meanwhile, dCellVax is still undergoing research and whatever the FDA response issues were, which we do not as yet know.
Koos and company just turned $50,000 into $500,000 on their books. For those of us that have invested that much or more over the past 2 years, how much value have we gotten from our money?
That's a perspective to keep in mind as well. The fact that this pattern can repeat itself because the company will need significant money for human trials. Will that also be cone with covertible notes that makes hundreds of thousands for the chosen few, while shareholders get nothing?
Sorry, but we're qualified to read and just might have other qualifications you are not aware of. Advice of "close your eyes", "don't think about it", "don't analyze your investments", "don't look at a company's history", but just blindly trust the CEO, would not rate very well as solid investment advice in my books.
Look, there are many lines of businesses out there that don't pay a fair wage, have their products made in China and are full of greed and unethical practices doing business with other businesses. And they have brand names and make a ton of money.
Pharma doesn't care who Koos is if they buy or license the science for their own purposes. Merger, no they won't "partner" in sharing the same business name. But if NR2F6 IP proves it can end one type of cancer, you think the CEOs of big pharma are so pristine in their practices, they will turn down a cure for cancer and billions in revenue because Koos is cut of the same cloth?
Now, who is not thinking this through? Why only see everything as bad? Oh, I forget, some are looking for shares on the cheap to flip.
Would you merge with a business that handled finances in this matter?
It matters because it might prevent a possible merger. People won't want to merger or co-develop. They'll only want to license or buy out and if Koos gets too greedy, his personality can shoot down those deals too. It is a concern and an ongoing one.
Look, one should point out the good and the bad and call it as it comes. I'll let my posts speak for themselves. The science is there and I see improvements on many levels. As I've stated more than once, my hope is in the Ichims and their willingness to put their patents and research on an 18 month timeclock for returns. They are bringing in other scientists to the board because of their research. They give the presentations, not Koos.
Can RGBP succeed with Koos? I hope so. Currently, I'm not confident that his actions in these areas are best for the company getting the best deal or the best interest of other companies, but if the FDA approves the IND, that's what will draw investors and money will come in. And if money comes in, Koos' ability or temptation to loan money to the company and pay himself back a hundred fold won't be needed.
That's my hope, and yes, even in spite of Koos, the science can bring us good returns. And what will most likely happen is, they won't partner with Koos, they'll either license the science and pay a "royalty" or they'll buy the science outright. Either scenario, the PPS goes up.
The only positive side of the $9,000,000 hit is that it isn't debt or cash loss. It's just a value giveaway to Koos and friends and it won't affect next quarter P/L.
But for any possible investment firm or doing their research into the business, it will be a red flag that they will look into further and to see this pattern of Koos loaning money and getting paid back with shares at a rate much higher than the "loans" will be a red flag and the fact they don't just pay up and wipe off these $1,000-$5,000 debts and expenses, but carry them forward with $500,000 in the bank doesn't make sense either.
They need a third party bookkeeper/accountant to take over bill paying and make it upfront and business like instead of RGBP being Koos' private banking/payoff system.
Well, the good and the bad of it. Good=we had over $500,000 in cash to pay people in cash. The Bad=the management still shows this is a company to benefit Mr. Koos first and foremost at the expense of others' stake.
1. Why did Koos not pay back his own $26,000 loan in cash and write it off the books like any normal business would. (Koos planning on giving himself some more preferred shares and/or common shares at .02/share to pay it off when cash runs out?
2. Why pay BMSN or ENTB amounts in common and preferred shares? (Because Koos owns those companies and the shares are worth more if company succeeds.
3. And the killer:
Material Changes in Results of Operations
Revenues from operations were $0 for the three months ended March 31, 2015 and -0- for the three months ended March 31 , 2014. Net Losses were $8,812,901 for the three months ended March 31, 2015 and $186,201 for the same period ended 2014.
The increase in Net Losses of approximately 4,633% is primarily attributable to the recognition of $8,179,432 of expenses recognized during the quarter ended March 31, 2015 resulting from the issuance for less than fair value of common shares in satisfactions of convertible notes issued by the Company.
Revenues from operations were $0 for the six months ended March 31, 2015 and -0- for the six months ended March 31 , 2014. Net Losses were $9,032,092 for the six months ended March 31, 2015 and $395,730 for the same period ended 2014.
The increase in Net Losses of approximately 2,182% is primarily attributable to the recognition of $8,179,432 of expenses recognized during the quarter ended March 31, 2015 resulting from the issuance for less than fair value of common shares in satisfactions of convertible notes issued by the Company.
No magic carpet ride. The selling volume has evaporated. No longer a sure flippers play until we get news to send this on next leg up and then if we go up 70%-300% on substantial news, the DTs and flippers will have their piece.
With CRL on the safety test clock, greater exposure for company from presentations, financials coming soon and greater company stability for future developments, the day to day extreme swings won't be so common anymore.
Very true. Furthermore, since these conferences publish all the various presentation summaries or descriptions into a "program", RGBP's research will be accessible to those in the field online.... and don't have to come across a RGBP PR to know about them.
These are not earthquake developments, but they are important and significant to the greater exposure and possibilities of cooperation with bigger fish that RGBP lacked in the past.
It's been a very positive year thus far and until we get "bad news", everything is looking much more positive and hopeful for HemaX success to be followed by the progression of other pipeline products without the numerous delays we've experienced in the past.
Success breeds success and if we get HemaXellerate I IND approval, Orphan Drug Status comes guaranteed upon filing and this will be a very different board.
Let's at least try to get a few facts straight. These were not all abstract presentations as you infer. In fact, it is a very significant point that RGBP and C. Ichim had submitted 3 abstracts to this conference and the conference heads, in looking over the topics and material, upgraded the abstracts to oral presentations.
In other words, the exact opposite of what you claim happened, happened. C. Ichim's material and subject matter was deemed by her "peers" to be of greater value than just an abstract and 2 of 3 became oral presentations.
Hardly the company scenario you put forward.
Well, many have told otherwise. All depends on whom one listens to.
Clearly, with CRL having to do "sophisticated" safety tests for toxicity, it's not an overnight venture and it was less than 2 weeks ago that the PR on the choice of CRL was made.
Sage. As long as CRL verifies the HemaX safety test results, i.e. they duplicate the results or better that RGBP had previously submitted, then the IND approval of HemaX by the FDA will put RGBP and all other pipeline products on the map.
Along with others on this board, I think that event will prove most significant and lasting in creating the volume, interest and price movement due to investment firm positions being taken in the company.
Until then, we can expect smaller fish in the aquarium along with sharp up and downs. Once we get first IND approval, current pricing should be a thing of the past.
When that will come people differ as to timeframe, but we all should feel better about CRL being part of the game and the potential future expansion of RGBP and the role CRL could play in moving new INDs through the process much quicker than RGBP has been able to do in the past.
Gotta get out of the gate first and things may spiral.
Amazingly quiet on all fronts here. New month, new anticipation, some quarter reports due shortly and knowledge that CRL should be working on HemaX safety testing.
Looking forward to an exciting Summer/Fall of news and company changing events with at least first IND approval this year.
Actually, the chart provided shows more positive still than negative since it has not closed under support. And tell tale is volume. As price has waned, down volume has evaporated. Until RGBP closes below support on increasing volume, this is still ready to pop up at this point.
Look at Acc/Dis line which is still climbing.
We see a large volume sell-off and close below MAs and chart changes. Until then, it is still in uptrend.
Hey, don't get too fuzzy on us. Today thus far is very remarkable in the low volume, but low volume and holding steady while markets around us are dropping and many biotechs are shedding profits isn't a bad thing.
You have to expect lulls in a stock unless it is a stock that is constantly being manipulated. Every stock has quiet periods, periods of consolidation etc.
We've had a flurry of PRs and changes in the company since Feb, cause for excitement and speculation. Stock recuperated from a low of .08 to currently holding in the 20s. Not all bad. Sure wish it was higher, but we shouldn't expect this to go up everyday. Legitimacy will come with IND approval. Before that, we will have more minor ebbs and flows with speculation and flippers.
But be patient. Turn off the ticker for a few days or put in a news alert or something. Ichim is at a conference spreading the word to build more interest and possible FUTURE partnerships. 10K will be coming in soon and every day that goes by is a day closer to getting news from CRL on safety testing of HemaX. My guess at this point is CRL testing news will be the next news to send this back over .40. We get an internationally respected company to verify the validity of HemaX and therefore upcoming IND approval and orphan drug status and at that point RGBP becomes a legitimate biotech company with potential in the eyes of those waiting and watching as to whether or not to invest. Right now, RGBP is high risk without an approval track record. One IND approval changes all that and a dominoe effect is possible when investors look at the pipeline potential and see dCellVax, IP on NR2F6/NR2F2 etc.
We are in a much better scenario now, more company stability than we were last year when everything was speculation. Give this a month for news to develop, but I think the summer is when we get the real fireworks.
The basics are ENTB is owned by BMSN and RGBP is a spinoff of BMSN whereas BMSN owns about 30Million shares of the RGBP float. For all sense and purposes, the focus of BMSN is on RGBP and RGBP has a much smaller float than BMSN. That said, as the value of RGBP increases, so does the value of BMSN.
Forgive my ignorance, but can someone help me out with the connection between RGBP, ENTB, and BMSN? I am a newer holder of RGBP only, but I am just a little lost on why there are multiple tickers. Any help is appreciated as I am new to investing in the medical field and I am sure this is something that I should know the reasoning for. TIA
People holding. The flippers are waiting for a drop below .20, but thus far the momentum down is halted as there is no reason to sell. Longs are waiting for future developments, more presentations coming up for the company, but not yet the impetus news to bring in new and larger investment firms.
Just checking in today, but from yesterday's PR, I think we are a few weeks away from further NR2F6 development news, i.e. "promising compound" being tested. In fact, because the compound is so critical and from compound to IND will include pre-clinical testing to build up data, we may or may not get a PR before the IND filing, depending on what compound, who owns it and whether the other partner wants to keep on lid on developments until IND in order to keep a leading edge on the research. Don't know, anybody guess how things will unfold.
I expect we get another PR after this conference that won't reflect any major change. Then at some point over the next month or so, I would hope for news on HemaX testing, maybe preferred shares symbol and if any developments outside HemaX and NR2F6.
Otherwise, we transition from whether something is going to happen or not to the fact that things are in pipeline development and we have to wait for HemaX test results and time for C. Ichim to process possibly hundreds of existing compounds with various tests to see which key fits the lock best for NR2F6.
But the fact things are quiet is an okay thing. Means people are waiting and we aren't in any "pump and dump" phase or people feeling that they can easily manipulate this back down to reload etc.
The more we travel sideways in silence, the stronger a new base will be formed.
Growing up takes time. Yes the substance of today's PR was already contained for the most part in previous PRs, except for the unquantified "interest" which could be anywhere from one person coming to the abstract to a dozen or more pharmaceutical reps having substantial interest in the developments C. Ichim put forward at the conference. Only time will tell.
2 things interested me in today's PR - 1. We have greater clarity on the "milestone" previously mentioned that C. Ichim has identified a specific molecular shape that adheres to and turns off the NR2F6 target. And from prvious PRs, we know that they have already begun a systematic routine of combing through existing drug compounds to identify matches in their proprietary ID process. This is real news and progress since, as she said, they've identified a specific keyhole and once they identify a key, we are basically pre-clinical trials away from a valid possible CURE (not treatment) to leukemia and other forms of cancer. If that happens, forget worrying about pennies. (But gentlemen, we are all conscious that this will take time. It's a process, not a game show hoping to win instantaneous prizes.)
2. In light of point 1. above, I see real potential possibility in RGBP identifying an established compound that fits the keyhole that might be owned by an established pharmaceutical company. And I see this as a plus, why? Think about what might happen if RGBP had to approach Bristol Myers with the news that their "X" drug compound might fit the RGBP cancer stem cell target (for which RGBP owns the IP) and cure cancer. Would Bristol-Myers be interested in co-developing the treatment? I believe YES! would be the answer.
So not only does RGBP not have to develop its own new drug, with the IP on the target and method of admin, their exposure and possibility of quick process to a cure may be facilitated by finding an existing small molecular compound owned by someone bigger and creates/opens a natural co-development relationship with a much bigger fish that puts RGBP on the map of every large investment firm. It's a WIN-WIN for RGBP.
Thanks. Makes sense to me. Like Rome, RGBP will not be built in a day. Just looking for steady progress and hopefully no more selling of shares for cash at .028.
Will be looking at financials in early May to see just where cash is at.
Exactly. What I'd like to know is what are the milestones revealed at the conference?
Since previous PRs mention that they are testing various existing compounds in their proprietary "hit" mechanism, have they identified any specific compounds to use? It would seem that once they identify the best "hit" candidates, they would be in contact with the company that owns the rights and one would expect either a PR on RGBP licensing rights to use the compound or a joint venture to use the drug along with RGBP's IP to pursue pre-clinical testing for a future IND.
Of course this doesn't happen in a day, but I would like to know what was said at the AACR.
Was the milestone the fact that they had identified a successful target as announced in the PR and that is all that will be said at this time?
Only time will tell.
Exactly, a timetable was discussed, but not released. It's all speculation, but since this is, according to the PR, a highly sophisticated safety test, I repeat that I doubt it is a month to FDA submission.
The more people get locked into high hopes of immediate results, the more chance people bail and new people are wary if it doesn't happen.
The fact that no time table was released, to me, means its probably a longer, not shorter timeframe.
Doubt you'll have to face that reality. That's not a bridge anyone, including the scientists, is expecting. Cross it when it comes up, but we could come up with all kinds of scenarios, like, what if the lab blows up from a terrorist attack, that would set us back as well....
Yes, frankly my gut feeling is that this would be the best case scenario for the company:
1. Leave the Ichims to do R&D, pipeline product suggestions and lab testing of potential treatments.
2. Use Scientific Advisory Board to review Ichims' work and pick the best candidates
3. At which point they partner with CRL to put together the plan for IND and contract CRL to cover all the testing and IND submission on their behalf.
Let Koos get on his boat and call in from time to time from some island and let Ichims and Cavens do the initial research, fund raising and R&D work.
Koos can sign the CRL agreements and I think we get quicker, more successful results and we all get heavier pockets from the PPS. The more the focus remains on the science, the potential and partners like CRL and less on RGBP being = Koos, the better.
Are you talking chemicals or stem cell treatments here?
Yes, if I drink poison, the effects are almost immediate and clear reaction, the LT effects of taking out cells, treating them and putting them back into the test client in order to see how the immune system reacts over time just might be a different time frame required by the FDA to monitor effects.
As I say, I'm not an expert, but I do read PRs carefully and with discernment.
I don't think we are 14 days away from IND safety test approval for what the PR states is a "sophisticated"animal safety study. You'd think a 14 day study could have been done multiple times over the past 2 years.
I'll be happy if it is sooner, but not clear from the first link you provided. Under toxicity reports, it listed:
TOXICITY STUDIES EFFICACY STUDIES
Acute, Subacute, Chronic, Local Tolerability
1, 3, 6, 9, 12 and 24 month chronic
Carcinogenicity and tumorogenicity
Biodistribution
Radiolabel and PCR
Histology
Immunohistochemistry
Combination device and stem cell toxicity
Custom toxicity studies
Good point. Plus with the safety experiments in CRL hands, the other positives are:
1. C and T Ichim can devote their time to other developments (we don't lose momentum)
2. Koos can't screw up the experiments They go forward on schedule according to the agreed upon timeline (when will they make that known? maybe after initial positive results in a month after which they just have to monitor for no surprise long term effects)
3. If HemaX is successful, easier to submit new drugs, experiments or even hand over IND submission of future INDs to CRL. May speed up the whole IND FDA approval.
Whereas, if they had chosen some unknown start up to save on expenses, the future would still be up in the air as to how well will things get done.
As I've said, the more things are out of Koos' hands and into the hands of scientists and professionals of the industry, the better off everyone, including Koos, is.
Thanks CT! That's a lot of work. For those who are new, you can see that in the past (prior to Jan 2015), although the science was there, the labs adn protocol was not. Even Min's experimental safety data in response to FDA didn't meet the FDA criteria, for GLP.
So today's news that CRL, an experienced and respected international company that provides pre-clinical, safety, drug discovery and even IND submittal on behalf of many companies, is taking over the safety data testing for HemaX (and maybe, hopefully, for all future INDs) is a very significant development for the successful and more rapid development of not only HemaXellerate, but other pipeline products, from R&D testing to IND approval.
No, but when the company gave a timeframe on dCellVax in the past, from my reading of the PR, the FDA toxicology tests (because you have to wait and verify whether there are any longer term effects, no just immediate side effects) was projected to take 4 months.
My non expert opinion therefore is this should be around the same timeframe putting us into August for final results most likely, and IND approval in September, which would be perfectly timed with the first restrictions coming off the convertible note shares and maximize the quick profits of Koos and friends.
So final HemaXellerate IND approval I now predict for Sep/Oct 2015 (now on the clock). Of course, that's not the only development we are looking at here.
Between now and Sept, we also expect to get news on further NR2F6 development, progression on dCellVax, possibly another IND and mid safety testing news on HemaX.
You don't grow up in a day, but today's news is a definite indicator that we are moving in the right direction.
Hey BG, we certainly hope not and I doubt that CRL makes deals with R&D companies based on shares. Cash only I would imagine and that is where the previously sold convertible notes come in. Next financials, from the PRs we've read, should show cash in bank of over $400,000 which I should think is enough to pay for a safety study.
In other words, no news can satisfy you. If you want IND approval, come back in a few months since nothing short of IND approval will be worthy news to you.
There are many noteworthy events in a child's life before graduation and getting a first job and they are celebrated.
We are watching a R&D company, formerly a one headed salesman, grow up before our eyes and the fact that the FDA approved everything but the safety studies for HemaXellerate regarding its IND makes today's news significant, because CRL is not a second rate lab and it gives us greater assurance for final IND approval upon submission of their studies. Having a known company with an extensive track record leaves less chance for error in the end and that is something shareholders can and should celebrate.
You're here to flip. You sold at .32 and wanted it to drop to .18 or lower to reload. Hey, don't bash us or the company for your decisions.
Is Regen Growing Up? Must say that so far, from what I've read, the choice of CRL seems to be a great one for validating that RGBP is finally serious about getting results and credibility. CRL trade on NYSE at 78 and seems to run the gammit of services.
Here's a link to their website relating to IND services (which is separate from their safety toxicology services) IND services
So, if RGBP and CRL develop a good working relationship, then once C. Ichim has identified what she wants to use for targeting NR2F6/NR2F2, RGBP could well hand over the prep, testing and IND to CRL - NOW THAT WOULD BE GREAT!
Here's hoping that C. Ichim's AACR presentation goes well with this news and the fact RGBP has chosen CRL gives them some greater legitimacy in the eyes of other scientists and investors.
Of course, the greatest confirmation of credibility would be the CRL testing verification of the original safety testing performed by RGBP.